Pembrolizumab
3 stories
-
healthZero Relapses in Landmark Bowel Cancer Immunotherapy Trial
Short-course immunotherapy before surgery eliminated relapses in bowel cancer patients over nearly three years.
-
healthNHS Rolls Out 1-Minute Immunotherapy Jab for Cancer Patients
A rapid pembrolizumab injection cuts treatment time by 90%, benefiting thousands with 14 cancer types on the NHS.
-
healthImmunotherapy Trial Shows No Cancer Recurrence After Nearly Three Years
A small bowel cancer trial shows pembrolizumab wiped out tumors in 59% of patients. After nearly three years, no recurrence.